Maribel Almonte, Raúl Murillo, Gloria Inés Sánchez, Paula González, Annabelle Ferrera, María Alejandra Picconi, Carolina Wiesner, Aurelio Cruz-Valdez, Eduardo Lazcano-Ponce, Jose Jerónimo, Catterina Ferreccio, Elena Kasamatsu, Laura Mendoza, Guillermo Rodríguez, Alejandro Calderón, Gino Venegas, Verónica Villagra, Silvio Tatti, Laura Fleider, Carolina Terán, Armando Baena, María de la Luz Hernández, Mary Luz Rol, Eric Lucas, Sylvaine Barbier, Arianis Tatiana Ramírez, Silvina Arrossi, María Isabel Rodríguez, Emmanuel González, Marcela Celis, Sandra Martínez, Yuly Salgado, Marina Ortega, Andrea Verónica Beracochea, Natalia Pérez, Margarita Rodríguez de la Peña, María Ramón, Pilar Hernández-Nevarez, Margarita Arboleda-Naranjo, Yessy Cabrera, Brenda Salgado, Laura García, Marco Antonio Retana, María Celeste Colucci, Javier Arias-Stella, Yenny Bellido-Fuentes, María Liz Bobadilla, Gladys Olmedo, Ivone Brito-García, Armando Méndez-Herrera, Lucía Cardinal, Betsy Flores, Jhacquelin Peñaranda, Josefina Martínez-Better, Ana Soilán, Jacqueline Figueroa, Benedicta Caserta, Carlos Sosa, Adrián Moreno, Juan Mural, Franco Doimi, Diana Giménez, Hernando Rodríguez, Oscar Lora, Silvana Luciani, Nathalie Broutet, Teresa Darragh, Rolando Herrero
INTRODUCTION: Human papillomavirus (HPV) testing is replacing cytology in primary screening. Its limited specificity demands using a second (triage) test to better identify women at high-risk of cervical disease. Cytology represents the immediate triage but its low sensitivity might hamper HPV testing sensitivity, particularly in low-income and middle-income countries (LMICs), where cytology performance has been suboptimal. The ESTAMPA (EStudio multicéntrico de TAMizaje y triaje de cáncer de cuello uterino con pruebas del virus del PApiloma humano; Spanish acronym) study will: (1) evaluate the performance of different triage techniques to detect cervical precancer and (2) inform on how to implement HPV-based screening programmes in LMIC...
May 24, 2020: BMJ Open